Literature DB >> 19132915

IL-17 and Th17 Cells.

Thomas Korn1, Estelle Bettelli, Mohamed Oukka, Vijay K Kuchroo.   

Abstract

CD4+ T cells, upon activation and expansion, develop into different T helper cell subsets with different cytokine profiles and distinct effector functions. Until recently, T cells were divided into Th1 or Th2 cells, depending on the cytokines they produce. A third subset of IL-17-producing effector T helper cells, called Th17 cells, has now been discovered and characterized. Here, we summarize the current information on the differentiation and effector functions of the Th17 lineage. Th17 cells produce IL-17, IL-17F, and IL-22, thereby inducing a massive tissue reaction owing to the broad distribution of the IL-17 and IL-22 receptors. Th17 cells also secrete IL-21 to communicate with the cells of the immune system. The differentiation factors (TGF-beta plus IL-6 or IL-21), the growth and stabilization factor (IL-23), and the transcription factors (STAT3, RORgammat, and RORalpha) involved in the development of Th17 cells have just been identified. The participation of TGF-beta in the differentiation of Th17 cells places the Th17 lineage in close relationship with CD4+CD25+Foxp3+ regulatory T cells (Tregs), as TGF-beta also induces differentiation of naive T cells into Foxp3+ Tregs in the peripheral immune compartment. The investigation of the differentiation, effector function, and regulation of Th17 cells has opened up a new framework for understanding T cell differentiation. Furthermore, we now appreciate the importance of Th17 cells in clearing pathogens during host defense reactions and in inducing tissue inflammation in autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19132915     DOI: 10.1146/annurev.immunol.021908.132710

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  1933 in total

Review 1.  T cells as therapeutic targets in SLE.

Authors:  José C Crispín; Vasileios C Kyttaris; Cox Terhorst; George C Tsokos
Journal:  Nat Rev Rheumatol       Date:  2010-05-11       Impact factor: 20.543

2.  Interleukin-17 is not required for classical macrophage activation in a pulmonary mouse model of Cryptococcus neoformans infection.

Authors:  Sarah E Hardison; Karen L Wozniak; Jay K Kolls; Floyd L Wormley
Journal:  Infect Immun       Date:  2010-10-04       Impact factor: 3.441

3.  TLR2 signaling and Th2 responses drive Tannerella forsythia-induced periodontal bone loss.

Authors:  Srinivas R Myneni; Rajendra P Settem; Terry D Connell; Achsah D Keegan; Sarah L Gaffen; Ashu Sharma
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

4.  Interleukin 10 modulation of pathogenic Th17 cells during fatal alphavirus encephalomyelitis.

Authors:  Kirsten A Kulcsar; Victoria K Baxter; Ivorlyne P Greene; Diane E Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-31       Impact factor: 11.205

5.  Macrophages participate in IL-17-mediated inflammation.

Authors:  Jobert G Barin; G Christian Baldeviano; Monica V Talor; Lei Wu; Sufey Ong; Farhan Quader; Ping Chen; Dongfeng Zheng; Patrizio Caturegli; Noel R Rose; Daniela Ciháková
Journal:  Eur J Immunol       Date:  2012-01-23       Impact factor: 5.532

Review 6.  Role of HLA class II genes in susceptibility and resistance to multiple sclerosis: studies using HLA transgenic mice.

Authors:  David Luckey; Dikshya Bastakoty; Ashutosh K Mangalam
Journal:  J Autoimmun       Date:  2011-05-31       Impact factor: 7.094

7.  VEGF-C mediated enhancement of lymphatic drainage reduces intestinal inflammation by regulating IL-9/IL-17 balance and improving gut microbiota in experimental chronic colitis.

Authors:  Xiaolei Wang; Jin Zhao; Li Qin
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

8.  The transcription factor Th-POK negatively regulates Th17 differentiation in Vα14i NKT cells.

Authors:  Isaac Engel; Meng Zhao; Dietmar Kappes; Ichiro Taniuchi; Mitchell Kronenberg
Journal:  Blood       Date:  2012-10-03       Impact factor: 22.113

9.  Mouse CD11b+Gr-1+ myeloid cells can promote Th17 cell differentiation and experimental autoimmune encephalomyelitis.

Authors:  Huanfa Yi; Chunqing Guo; Xiaofei Yu; Daming Zuo; Xiang-Yang Wang
Journal:  J Immunol       Date:  2012-10-03       Impact factor: 5.422

10.  Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling.

Authors:  Mathew T Mizwicki; Milan Fiala; Larry Magpantay; Najib Aziz; James Sayre; Guanghao Liu; Avi Siani; Derrick Chan; Otoniel Martinez-Maza; Madhuri Chattopadhyay; Antonio La Cava
Journal:  Am J Neurodegener Dis       Date:  2012-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.